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ABSTRACT
Most clinical isolates of Staphylococcus aureus harbour genes encoding superantigenic toxins that bind the
Vb domain of T-cells, but little information is available concerning superantigenic toxin production
during staphylococcal toxic shock syndrome (TSS) and septic shock. This prospective study investigated
14 patients with staphylococcal TSS or septic shock; the toxin gene profile of each isolate was determined
and flow-cytometry was used to identify the discriminant Vb signature (DVbS) of each superantigenic
toxin in vitro. Attempts were also made to identify in-vivo production of superantigenic toxin DVbS in
patients’ blood. The DVbS identified in vitro were: toxic shock syndrome toxin (TSST)-1, Vb 2;
staphylococcal enterotoxin (SE), Vb 9, Vb 22; SEB, Vb 3, Vb 14, Vb 17; SED, Vb 1, Vb 8; egc, Vb 5.3,
Vb 7.1, Vb 9, Vb 23; and SElK, Vb 5.1. The DVbS of TSST-1 and SEB were detected in patients with
menstrual and non-menstrual TSS, respectively, whereas no Vb signature was detected during septic
shock. All patients with septic shock (but only one patient with TSS) had lymphopenia and ⁄ or impaired
cellular immunity. Detection of a superantigenic toxin DVbS may help to show which toxin is produced
during staphylococcal TSS, thus confirming the diagnosis and hastening the administration of anti-toxin
therapy. In contrast, this approach failed to demonstrate superantigenic toxin involvement in cases of
septic shock. In this latter condition, a superantigenic toxin may not be produced by S. aureus, or its
production may occur without expansion of targeted T-cells because of T-cell apoptosis and ⁄ or anergy.
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INTRODUCTION
Staphylococcus aureus produces a wide range of
toxins that interact with the immune system.
Superantigenic toxins, also called pyrogenic toxin
superantigens, which include toxic shock syn-
drome toxin-1 (TSST-1) and staphylococcal en-
terotoxins (SEA, SEB, etc.), mediate a potent
activation of immune cells [1,2]. These molecules
bypass normal antigen presentation pathways by
cross-linking major histocompatibility complex
class II molecules on antigen-presenting cells to
the Vb domain of the T-cell receptor [1,2]. In this
way, each superantigenic toxin selectively stimu-
lates and expands one or several Vb subsets,
thereby producing a Vb signature for each super-
antigenic toxin [2–4]. Except for Vb 2, which is
specific to TSST-1, a given Vb subset may be
expanded by different superantigenic toxins, and
the discriminant Vb signature (DVbS) of each
superantigenic toxin (i.e., the combination of Vb
subsets specific to a given superantigenic toxin) is
unknown [2–4]. The massive T-cell activa-
tion mediated by superantigenic toxins leads
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to uncontrolled release of pro-inflammatory cyto-
kines, which are responsible for clinical manifes-
tations of toxin-mediated diseases, e.g., toxic
shock syndrome (TSS) [2,5].
TSST-1 was first identified in the 1980s as the
toxin responsible for menstrual TSS, while both
TSST-1 and enterotoxins are involved in non-
menstrual TSS [6,7]. For many years, the iden-
tification of superantigenic toxins involved in
TSS was based mainly on the in-vitro toxin
production or toxin gene content of an isolate
[6,8–10]. However, superantigenic toxins are also
produced by S. aureus isolates from patients
without TSS [11]. This includes patients with
septic shock, thereby adding to the controversy
surrounding the involvement of superantigenic
toxins in the pathogenesis of S. aureus septic
shock [12].
It has been shown previously that the in-vivo
Vb signature of superantigenic toxins can be used
to confirm a diagnosis of TSS [13,14]; indeed,
expansion of Vb 2 T-cells, which corresponds to
TSST-1 superantigenic activity, has been detected
in patients with TSS [13–15]. Selective expansion
of Vb T-cells has not yet been investigated in
patients with enterotoxin-associated non-men-
strual TSS or in patients with S. aureus septic
shock. The purpose of the present study was to
detect in-vivo production of superantigenic toxins
early after onset of staphylococcal TSS and septic
shock. An attempt was made to identify super-
antigenic toxin DVbS in peripheral blood mono-
nuclear cells (PBMCs) of patients who had been
enrolled prospectively after determination of (i)
the toxin gene profile of each isolate and (ii) the
DVbS obtained in vitro by flow-cytometry with
the culture supernatant of the corresponding
S. aureus isolate.
MATERIALS AND METHODS
Patients and clinical data
Patients with S. aureus TSS or septic shock were enrolled
prospectively between 1 January 2006 and 31 December 2006.
The study was approved by the local ethics committee. Septic
shock was defined according to the criteria of the American
College of Chest Physicians ⁄ Society of Critical Care Medicine
Conference [16]. S. aureus TSS was defined according to CDC
criteria [17].
The following data were recorded for all patients: demo-
graphical characteristics (age, gender), underlying disorders
associated with impaired cellular immunity (haematological
immunosuppressive disease, ongoing malignancy, infection
with human immunodeficiency virus, cirrhosis, etc.) and
current corticosteroid therapy (>1 month) or other immuno-
suppressive therapy. Therapy with antimicrobial agents and
intravenous immunoglobulin was also recorded, and the 28-
day mortality rate was determined.
Microbiological investigations
S. aureus isolates from vaginal swabs and other sites of
infection were identified by standard microbiological methods,
including Gram’s stain and use of the Phoenix Automated
Microbiology System (Becton Dickinson Biosciences, Franklin
Lakes, NJ, USA). Each S. aureus isolate was also tested for
production of coagulase (bioMe´rieux, Marcy-l’Etoile, France),
catalase and clumping factor (Pastorex Staph-plus; Bio-Rad,
Hercules, CA, USA).
Genomic DNA was extracted from all isolates and analysed
by PCR for genes encoding various superantigenic toxins, i.e.,
TSST-1, SEA, SEB, SEC, SED (isolates positive for the gene
encoding SED were also considered to be positive for the gene
encoding SEJ, as these two genes are located on the same
plasmid), SEH, SElK, SElL, SElM, SElO (isolates positive for
genes encoding SElM and SElO were also considered to be
positive for SEG, SEI and SEN, as they form part of a single
operon known as the enterotoxin gene cluster, egc), SElP, SElQ
and SElR [4,18]. The mecA gene coding for methicillin resis-
tance was also detected by PCR [10].
Flow-cytometry
In-vitro determination of the DVbS of individual superantigenic
toxins. Culture supernatants of each clinical isolate, grown for
24 h at 37C with vigorous shaking in RPMI-1640 medium
(Invitrogen, Paisley, UK) supplemented with fetal bovine
serum (Invitrogen) 5% v ⁄v, were filtered (Sartorius 0.20-lm
Minisart; VivaSciences, Hannover, Germany) and used to
stimulate PBMCs (2 · 106 ⁄mL) purified from two healthy
donors by Ficoll density gradient sedimentation (PANCOLL;
PAN Biotech GmbH, Aidenbach, Germany). After incubation
for 2 days, the cells were washed twice in phosphate-buffered
saline (Invitrogen) and resuspended in fresh RPMI-1640
medium supplemented with heat-inactivated fetal bovine
serum 10% v ⁄v, 20 mM HEPES buffer, 2 mM L-glutamine
(Sigma-Aldrich, Poole, UK), streptomycin and penicillin
(Invitrogen) 100 mg ⁄L in 24-well Falcon plates (Becton
Dickinson) for 9 days. The medium was changed every
3 days. After culture for 11 days, PBMCs were labelled with
anti-CD3 and anti-Vb antibodies (24 Vb antibodies are
quantified in the Immunotech IO Test b Mark; Beckman
Coulter, High Wycombe, UK) according to the supplier’s
instructions. The Vb repertoire was determined by flow-
cytometry (FACScan; Becton Dickinson) and the multiparam-
eter data files were analysed with the Cellquest program
(Becton Dickinson). To assign the DVbS of a given superan-
tigenic toxin, the Kruskal–Wallis non-parametric test was
used to compare the percentage of each Vb subset, obtained
for all isolates, in the presence and absence of each super-
antigenic toxin gene, with p <0.05 considered to be statisti-
cally significant. Finally, by combining all the results, a single
Vb subset, or a combination of Vb subsets, was considered to
be the DVbS of the corresponding toxin. The results obtained
were compared with those published previously [3,4,15,
19–29].
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Determination of the Vb repertoire in patients with staphylococcal
toxic or septic shock and detection of a superantigenic toxin DVbS
in blood. The Vb repertoire of each patient was determined as
early as possible during the first 10 days after the onset of
symptoms. PBMCs from the patients were purified by Ficoll
density gradient sedimentation and immediately labelled with
anti-CD3 and anti-Vb antibodies to determine the Vb reper-
toire (see above). When possible, the Vb repertoire of each
patient was also determined after c. 1 week in order to detect
changes in the Vb pattern with time. Control values for each
Vb subset were obtained using samples from 39 healthy
donors. For each Vb subset, a positive cut-off value for Vb
expansion in vivo was taken as the mean plus two standard
deviations of the values obtained for the same Vb subset in the
controls.
RESULTS
Clinical characteristics
Fourteen patients were enrolled in this study, five
with S. aureus TSS (three menstrual and two non-
menstrual cases) and nine with S. aureus septic
shock. The demographical characteristics and
medical histories of these patients are summarised
in Table 1. Patients with TSS had a mean age of
30 years (range 18–63 years) and no history of
immunosuppression; only one patient had tran-
sient lymphopenia (patient 5), and all survived
at day 28. Patients with septic shock were
older (mean age 61 years, range 35–85 years) and
lymphopenia was present in all eight patients
tested, with four (44%) patients having a medical
history of cellular immunosuppression. Five
(56%) of these patients died before day 28. Except
for patients 1 and 2 (who had only postural
hypotension), all patients required admission to
an intensive care unit and vaso-active drug ther-
apy (e.g., norepinephrine) after fluid resuscitation.
Microbiological findings
Among the three patients with menstrual TSS
(Table 1), one received antimicrobial therapy
before swabs were taken and S. aureus was not
recovered. The two available isolates responsible
for menstrual TSS were positive for the tst gene
and for the egc locus. There were two patients
with non-menstrual TSS (Table 1); S. aureus grew
in culture from the surgical wound of patient 4,
but the isolate from patient 5 was lost before the
toxin gene profile could be determined. The only
available isolate responsible for non-menstrual
TSS possessed the sea, seb and sed genes. Among T
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the nine isolates responsible for septic shock, five
harboured the sea gene (plus sed, selr, selk or selq
in four cases), while two were positive only for
the egc locus. One isolate was negative for all the
superantigenic toxin genes tested. Among the
total of 12 S. aureus isolates, four were positive for
the mecA gene (three of which corresponded to
the predominant hospital-acquired methicillin-
resistant S. aureus clone in France), and these four
isolates were responsible for septic shock.
In-vitro determination of the Vb signature of
superantigenic toxins
To determine which Vb subset was expanded
significantly in the presence of each superanti-
genic toxin gene, the Vb subset obtained with an
isolate positive for the gene encoding a given
superantigenic toxin (e.g., the sea gene) was
compared with the results obtained for the iso-
lates negative for this gene. Using this approach,
the DVbS was Vb 2 for TSST-1, Vb 9 and Vb 22
for SEA, Vb 3, Vb 14 and Vb 17 for SEB, and Vb 1
and Vb 8 for SED (Table 2). The DVbS of super-
antigenic toxins encoded by the egc locus was
Vb 5.3, Vb 7.1, Vb 9 and Vb 23. The selk and selq
genes, which were always jointly present in the
isolates investigated, were associated significantly
with Vb subset 5.1. In contrast to the other toxins,
no specific Vb T-cell expansion was revealed in
response to isolates positive for SElR.
Detection of a superantigenic toxin DVbS in
peripheral blood
The Vb repertoire in PBMCs from each patient
with S. aureus TSS or septic shock is shown in
Table 3 and Fig. 1. A Vb 2 T-cell expansion was
observed in the three patients with menstrual
TSS, even when the corresponding isolates
showed in-vitro expansion not only of Vb 2, but
also of other Vb subsets corresponding to the
production of SEA and egc-encoded superanti-
genic toxins. In patient 2, the percentage of the
Vb 2 subset was initially less than two standard
deviations above that of the controls, but rose
two-fold within 9 days (Fig. 1). As this case fully
corresponded to the case definition, it was con-
sidered that the two-fold expansion of a Vb
subset, albeit less than two standard deviations
above that of the controls, could result from
superantigenic toxin activation.
In the two non-menstrual TSS cases, the SEB
DVbS was detected. Vb 3, Vb 14 and Vb 17 were
Table 2. In-vitro production in culture supernatants of 12 Staphylococcus aureus isolates of discriminant Vb signatures
(p values shown in bold) for each superantigenic toxin investigated
Toxins Vb signatures described previously Ref. Genesa
Discriminant expanded Vb subsets comprising each discriminant Vb signature (p values)
Vb 1 Vb 2 Vb 3 Vb 5.1 Vb 5.2 Vb 5.3 Vb 7.1 Vb 7.2 Vb 8 Vb 9 Vb 14 Vb 17 Vb 22 Vb 23
TSST-1 2 [3,15] tst – <0.001 – – – – – – – – – – – –
SEA 1, 5.1, 5.2, 5.3, 6.4, 7.2, 8, 9, 16,
18, 21.3, 22, 23
[3,22,24] sea – – – – – – – – – 0.004 – – 0.02 –
SEB 3, 6.4, 12, 13.2, 14, 15, 17, 20 [3,15,24] seb – – 0.04 – – – – – – – 0.02 0.02 – –
SEC 3, 6.4, 12, 13.2, 14, 15, 17, 20 [3,19] – –
SED 1, 5.3, 6.9, 7.4, 8, 12 [3,23] sed <0.001 – – – – – – – <0.001 – – – – –
SEJ ND –
SEE 5.1, 6.3, 6.4, 6.7, 6.9, 8, 16, 18, 21.3 [3,20,21] –
egc egcb – – – – – 0.04 0.007 – – 0.005 – – – 0.049
SEG 3, 12, 13.1, 13.2, 13.6, 14, 15 [3,4] – – – – – – – – – – – – – –
SEI 1, 5.1, 5.2, 5.3, 6, 23 [3,4] – – – – – 0.04c – – – – – – – –
SElM 5.1, 5.2, 5.3, 6, 18, 21.3, 23 [3,4] – – – – – 0.04c – – – – – – – 0.049f
SElN 5.1, 5.2, 5.3, 9 [3,4] – – – – – 0.04c – – – 0.005e – – – –
SElO 5.1, 7.1 [3,4] – – – – – – 0.007d – – – – – – –
SElP 5.1, 6, 8, 16, 18, 21.3 [25] –
SElK 5.1, 5.2, 6.7 [3,28] selk – – – <0.001 – – – – – – – – – –
SElQ 2, 5.1, 5.2, 6.7, 21.3 [3,29] se1q – – – <0.001 – – – – – – – – – –
SElL 5.1, 5.2, 6.7, 7, 9, 16, 22 [3,27] –
SElR 3, 11, 12, 13.2, 14 [3,26] se1r 0.002g – – – – – – 0.017g 0.004g – – – – –
TSST-1, toxic shock syndrome toxin-1; SE, staphylococcal enterotoxin; SEl, staphylococcal enterotoxin-like; ND, not done.
aGenes encoding superantigenic toxins detected in the 12 isolates included in this study.
bAfter exclusion of two isolates both positive for the egc locus and tst.
cVb subset associated significantly with the egc locus included in the Vb signature of SEI, SElM, SElN.
dVb subset associated significantly with the egc locus corresponding to the Vb signature of SElO.
eVb subset associated significantly with the egc locus included in the Vb signature of SElN.
fVb subset associated significantly with the egc locus included in the Vb signature of SElM.
gNot considered to be a Vb subset associated significantly with SElR, as the two isolates positive for selr were also positive for the sea (Vb 9 and Vb 22 were expanded, but not
significantly, and even if Vb 7.2 was not associated significantly with the discriminant Vb signature of SEA in the present study, this is one of the Vb subsets targeted by SEA)
and the sed genes.
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expanded by more than two standard deviations
above the control values in patient 4 (Fig. 1). In
patient 5, the Vb 14 subset was expanded by
more than two standard deviations above the
control values, and the Vb 3 and Vb 17 subsets
increased 2.5- and 1.6-fold, respectively, within
7 days, whereas no other Vb subsets increased
(Fig. 1). In patient 4, the isolate that produced SEB
also produced SEA and SED in vitro, as the Vb
subset corresponding to the DVbS of these toxins
was expanded. No Vb expansion was observed in
six of the nine cases of septic shock (Table 3,
Fig. 1). In the other three cases of septic shock,
one showed Vb 2 and Vb 3 expansion, a second
showed Vb 14 expansion, and the third showed
Vb 8 expansion. In contrast to the cases of TSS,
none of these expansions correlated with the
results obtained with the corresponding isolates
in vitro.
DISCUSSION
This study revealed that nearly all the cases of TSS
were associated with specific Vb expansion,
whereas no specific T-cell modifications were
found in patients with septic shock, despite the
presence of superantigenic toxin genes in the
corresponding isolates and their expression
in vitro. As most clinical isolates of S. aureus
responsible for TSS and septic shock harbour
two or more superantigen-encoding genes [9,12],
it was first necessary to determine the precise
DVbS corresponding to each toxin. TSST-1 is
known to activate only the Vb 2 subset in vitro
[3,15]. A Vb signature has also been documented
for most enterotoxins in vitro, but the situation is
not straightforward as: (i) a given Vb subset may
be part of the Vb signature of different enterotox-
ins; (ii) most enterotoxins are associated with the
expansion of multiple Vb subsets; (iii) some Vb
subsets are considered to be major or minor
components of the Vb signature of a given
enterotoxin; and (iv) discriminant combinations
of Vb subsets (i.e., the DVbS) are not known for
each enterotoxin [2,3]. To our knowledge, the
present investigation is the first study to deter-
mine the discriminant Vb signatures of superan-
tigenic toxins, especially enterotoxins, produced
by clinical isolates of S. aureus. For example, the
study revealed that only Vb 9 and Vb 22 formed
the DVbS of SEA (despite previous reports of the
possible expansion of 13 different Vb subsets;
Table 2), and that only Vb 3, Vb 14 and Vb 17
comprised the DVbS of SEB (despite previous
reports of the possible expansion of eight different
Vb subsets; Table 2) [3,22,24]. Determining the
Table 3. In-vivo production of superantigenic toxins according to the Vb signature defined in vitro
Patient no.
Clinical data Microbiological data Flow-cytometry investigation
Clinical
diagnosis
CDC criteria
for TSS mecA
Toxin gene
profile
Vb expansion detected
in the patient’s blooda
In-vivo detection of
superantigenic toxin
1 mTSS Yes (probableb) ND ND Vb 2 TSST-1
2 Recurrent mTSS Yes (confirmed) No tst, egc Vb 2 TSST-1
3 mTSS Yes (probableb) No tst, sea, egc Vb 2 TSST-1
4 nmTSS Yes (confirmed) No sea, seb, sed Vb 3, Vb 14, Vb 17 SEB
5 nmTSS Yes (confirmed) ND ND Vb 3, Vb 14, Vb 17 SEB
6 Septic shock No Yesc sea, sed Noned –
7 Septic shock No No egc Vb 2, Vb 3, Vb 5.1e –
8 Septic shock No No None None –
9 Septic shock No Yesc sea, sed, selr None –
10 Septic shock No Yesc sea, sed, selr None –
11 Septic shock No Yes egc Vb 14f –
12 Septic shock No No sea, selk, selq Noned –
13 Septic shock No No sea Vb 8g –
14 Septic shock No No egc None –
ND, not done; mTSS, menstrual toxic shock syndrome; nmTSS, non-menstrual toxic shock syndrome; TSST, toxic shock syndrome toxin; SEB, staphylococcal enterotoxin B.
aVb subsets expanded by more than two standard deviations above that of the controls are shown in bold; Vb subsets expanded by less than two standard deviations above the
controls, but with >1.5-fold variation between two time-points, are not shown in bold; Vb subsets comprising a detected DVbS are underlined.
bThe diagnosis of TSS could not be confirmed, as the patient was lost to follow-up after discharge (2 weeks after admission) and no information was available concerning
desquamation.
cCorresponding to the predominant clone of methicillin-resistant Staphylococcus aureus detected in France.
dThe T-cell Vb repertoire was determined once, at the onset of symptoms.
eMinor expansion of Vb 2-positive T-cells (17.7%, without tst gene detection) and minor expansion of Vb 3-positive T-cells (slightly above two standard deviations of that of
the controls, without expansion of Vb 14 and Vb 17 and without detection of the seb gene) were detected. The expansion of Vb 5.1 was less than two standard deviations above
that of the controls, but fell 1.6-fold between the two time-points (without detection of the selk gene).
fThe value of Vb 14 increased by more than two standard deviations (8.5%) above that of the controls between day 7 (7.02%) and day 14 (10.5%) and remained mildly
elevated (11.5%) on day 28 (without expansion of Vb 3 or Vb 17 and without detection of the seb gene).
gThe value of Vb 8 increased by more than two standard deviations (5.3%) above that of the controls between day 1 (5%) and day 11 (6.73%) (without expansion of Vb 1 and
without detection of the sed gene).
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DVbS by analysing the T-cell Vb repertoire in a
patient’s blood may therefore be a rapid (a few
hours) and reliable method of detecting produc-
tion of superantigenic toxins in vivo, thereby
guiding the use of anti-toxin agents (e.g., antibi-
otics to block toxin production, or intravenous
immunoglobulin to block toxin activity in vitro)
[30]. At present, identification of superantigenic
toxins is based mainly on detection of the corre-
sponding gene [9]. However, most clinical S. aur-
eus isolates responsible for TSS and septic shock
harbour at least one gene encoding a superanti-
genic toxin if newly described enterotoxins, e.g.,
those encoded by the egc locus, are included
[9,11,12,31].
Biological criteria are needed for early diagno-
sis of TSS, as the full CDC case definition of
‘definite’ TSS includes desquamation, which may
Fig. 1. Vb repertoire of two patients with menstrual toxic shock syndrome (TSS), two patients with non-menstrual TSS,
and two patients with septic shock. The data reveal a superantigenic toxin Vb signature during TSS, but not during septic
shock. , Vb expansion of more than two standard deviations above that of the controls; , Vb expansion of less than two
standard deviations above that of the controls, but with >1.5-fold variation of a Vb subset between two time-points. NA,
data not available; TSST-1, toxic shock syndrome toxin-1; SE, staphylococcal enterotoxin.
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occur only several weeks after the onset of
symptoms [2,5]. It has been proposed that other
biological criteria, e.g., the absence of acute-phase
antibodies against TSST-1, should be included to
facilitate early diagnosis of TSS [32]. The present
study revealed specific Vb 2 expansion in the
three patients with menstrual TSS, which con-
firmed the findings of previous case reports. This
specific T-cell expansion reflected a pathogenic
role of TSST-1, since: (i) only TSST-1 is responsible
for menstrual TSS; (ii) the isolates carried the
gene encoding TSST-1; (iii) Vb 2 expansion was
observed both in the patient’s blood and with the
culture supernatant in vitro; and (iv) TSST-1 is
the only superantigenic toxin known to target the
Vb 2 subset. In patient 2, who had recurrent TSS,
Vb 2 expansion was only minor, perhaps because
of Vb 2-positive T-cell anergy. Indeed, immuno-
logical tolerance and anergy towards a Vb tar-
geted by a superantigenic toxin have been
described in animal models challenged repeat-
edly with the same superantigenic toxin, and also
in humans after a first episode of neonatal TSS-
like exanthematous disease, which is another
TSST-1-associated disease [33,34]. Vb 3, Vb 14
and Vb 17 expansion was observed in the two
cases of non-menstrual TSS. In at least one case
(patient 4), specific T-cell expansion revealed SEB
intoxication, as: (i) few enterotoxins (only SEB and
SEC) can induce concomitant expansion of Vb 3,
Vb 14 and Vb 17 [3]; (ii) the isolate carried the
gene encoding SEB; and (iii) Vb 3, Vb 14 and
Vb 17 expansion was observed in the patient’s
blood, and it was demonstrated that these subsets
corresponded to the SEB DVbS in vitro. In the
second non-menstrual case (patient 5), it was not
possible to clearly demonstrate the involvement
of SEB, as the isolate was lost before analysis of
toxin genes and culture supernatant assays could
be performed. However, the patient fulfilled all
the criteria for TSS (including desquamation) and,
15 days after the onset of symptom, Vb 14 expan-
sion associated with Vb 3 and Vb 17 expansion
was detected, corresponding to the SEB DVbS. It
is noteworthy that this patient with TSS devel-
oped profound lymphopenia (reported infre-
quently during TSS) early in the disease, and
that normal values returned by the time that the
SEB DVbS was detected. In the early stage of
the disease, transient depletion has been
described before T-cell expansion, possibly fol-
lowing mobilisation from peripheral blood
and accumulation in lymph nodes or the spleen
[34].
During septic shock, several lines of evidence
suggest that superantigenic toxins and other
virulence factors may act in concert, resulting in
overlap between toxic shock and septic shock in a
type of ‘mixed shock’ [35]. First, it has been
shown previously that the presence of the sea
gene correlates with the onset of septic shock
during S. aureus infection [12]. Second, vaccina-
tion with modified SEA, SEC or TSST-1 lacking
superantigenic properties confers protection in
animal models of sepsis induced by S. aureus
strains producing SEA, SEC or TSST-1 in vitro
[36–38]. No DVbS were detected in patients with
septic shock, supporting the hypothesis that
superantigenic toxins are not produced in vivo
during septic shock. The slight Vb expansion
observed during septic shock did not correspond
to that observed in vitro with the corresponding
isolates. These results indicate that: (i) superanti-
genic toxin is not produced during S. aureus
septic shock; or (ii) the Vb expansion pick time
has been missed in patients with septic shock (as
described in a few patients with TSS [15]); or (iii)
that superantigenic toxin production occurs with-
out expansion of targeted T-cells. The last possi-
bility could be explained by T-cell apoptosis
and ⁄ or anergy [39]. Apoptosis is an early event
during the course of septic shock, leading rapidly
to profound lymphopenia [40]. All of the septic
shock patients (but only one TSS patient) had
lymphopenia, and four of them also had impaired
cellular immunity resulting from underlying ill-
ness or immunosuppressive therapy. Minor
‘expansion’ of Vb 2-positive T-cells was detected
in a patient infected by a strain that did not
produce TSST-1. Minor expansion of Vb 14- and
Vb 8-positive T-cells was also revealed in two
other patients, respectively, but these ‘expansions’
did not correspond to any DVbS. This might be
because lymphopenia results from differential
apoptosis among the 24 major Vb subsets. As a
consequence, during septic shock, T-cell Vb expan-
sion in response to superantigenic toxins might be
limited by apoptosis and ⁄ or by anergy, which
perhaps explains why it is difficult to demonstrate
superantigen involvement in this setting.
A limitation of this study was the small number
of patients studied, especially patients with TSS.
However, TSS is rare in France, with only one
case per 106 inhabitants per year. Also, markers of
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T-cell activation, e.g., CD45RO, used in neonatal
TSS-like exanthematous disease or in some TSS
cases associated with TSST-1 production [14,34],
were not employed. Activation of an expanded
Vb subset may provide indications of superanti-
gen production, and may be useful for
distinguishing expansion caused by superanti-
gen toxins from relative expansion caused by
age-related changes in the T-cell repertoire or
proliferative disorders, e.g., myeloma, myelodys-
plasic syndromes and T-cell lymphoproliferation
[41,42]. However, each patient was sampled on
several occasions in order to detect short-term
variations in a Vb subset that may provide
information about its putative stimulation and
expansion. In a previous study, Kamel et al. [43]
failed to demonstrate a clear-cut correlation
between results in vivo and in vitro in patients
with multiple myeloma and non-menstrual toxic
shock or septic shock.
In conclusion, analysis of the Vb T-cell reper-
toire appears to be useful for detecting the
superantigenic toxin DVbS in vivo. This may help
to confirm the diagnosis of TSS and hasten the
administration of anti-toxin therapy. Further
investigations (e.g., analysis of apoptosis of puta-
tive targeted Vb subsets) are required to demon-
strate in-vivo production of superantigenic toxins
during S. aureus septic shock.
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